These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

317 related items for PubMed ID: 7588796

  • 1. Urokinase-type plasminogen activator/type-2 plasminogen-activator inhibitor complexes are not internalized upon binding to the urokinase-type-plasminogen-activator receptor in THP-1 cells. Interaction of urokinase-type plasminogen activator/type-2 plasminogen-activator inhibitor complexes with the cell surface.
    Ragno P, Montuori N, Rossi G.
    Eur J Biochem; 1995 Oct 15; 233(2):514-9. PubMed ID: 7588796
    [Abstract] [Full Text] [Related]

  • 2. Processing of complex between urokinase and its type-2 inhibitor on the cell surface. A possible regulatory mechanism of urokinase activity.
    Ragno P, Montuori N, Vassalli JD, Rossi G.
    FEBS Lett; 1993 Jun 01; 323(3):279-84. PubMed ID: 8388810
    [Abstract] [Full Text] [Related]

  • 3. Purified alpha 2-macroglobulin receptor/LDL receptor-related protein binds urokinase.plasminogen activator inhibitor type-1 complex. Evidence that the alpha 2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes.
    Nykjaer A, Petersen CM, Møller B, Jensen PH, Moestrup SK, Holtet TL, Etzerodt M, Thøgersen HC, Munch M, Andreasen PA.
    J Biol Chem; 1992 Jul 25; 267(21):14543-6. PubMed ID: 1378833
    [Abstract] [Full Text] [Related]

  • 4. Regions involved in binding of urokinase-type-1 inhibitor complex and pro-urokinase to the endocytic alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Evidence that the urokinase receptor protects pro-urokinase against binding to the endocytic receptor.
    Nykjaer A, Kjøller L, Cohen RL, Lawrence DA, Garni-Wagner BA, Todd RF, van Zonneveld AJ, Gliemann J, Andreasen PA.
    J Biol Chem; 1994 Oct 14; 269(41):25668-76. PubMed ID: 7929271
    [Abstract] [Full Text] [Related]

  • 5. Internalization of the urokinase-plasminogen activator inhibitor type-1 complex is mediated by the urokinase receptor.
    Olson D, Pöllänen J, Høyer-Hansen G, Rønne E, Sakaguchi K, Wun TC, Appella E, Danø K, Blasi F.
    J Biol Chem; 1992 May 05; 267(13):9129-33. PubMed ID: 1315748
    [Abstract] [Full Text] [Related]

  • 6. alpha-2 Macroglobulin receptor/Ldl receptor-related protein(Lrp)-dependent internalization of the urokinase receptor.
    Conese M, Nykjaer A, Petersen CM, Cremona O, Pardi R, Andreasen PA, Gliemann J, Christensen EI, Blasi F.
    J Cell Biol; 1995 Dec 05; 131(6 Pt 1):1609-22. PubMed ID: 8522616
    [Abstract] [Full Text] [Related]

  • 7. A hybrid protein of urokinase growth-factor domain and plasminogen-activator inhibitor type 2 inhibits urokinase activity and binds to the urokinase receptor.
    Ballance DJ, Marshall JM, Cottingham IR, Steven J, Berry SJ, Cederholm-Williams SA, Goodey AR, Courtney M.
    Eur J Biochem; 1992 Jul 01; 207(1):177-83. PubMed ID: 1321039
    [Abstract] [Full Text] [Related]

  • 8. Urokinase-type plasminogen-activator receptor associates to a cell surface molecule in monocytic cells.
    Ragno P, Montuori N, Rossi G.
    Biochem Biophys Res Commun; 1996 Jul 05; 224(1):252-7. PubMed ID: 8694822
    [Abstract] [Full Text] [Related]

  • 9. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
    Ohba K, Miyata Y, Kanda S, Koga S, Hayashi T, Kanetake H.
    J Urol; 2005 Aug 05; 174(2):461-5. PubMed ID: 16006865
    [Abstract] [Full Text] [Related]

  • 10. Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor.
    Cubellis MV, Andreasen P, Ragno P, Mayer M, Danø K, Blasi F.
    Proc Natl Acad Sci U S A; 1989 Jul 05; 86(13):4828-32. PubMed ID: 2544876
    [Abstract] [Full Text] [Related]

  • 11. Protease nexin-1-urokinase complexes are internalized and degraded through a mechanism that requires both urokinase receptor and alpha 2-macroglobulin receptor.
    Conese M, Olson D, Blasi F.
    J Biol Chem; 1994 Jul 08; 269(27):17886-92. PubMed ID: 8027043
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Binding of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex to the endocytosis receptors alpha2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor.
    Rodenburg KW, Kjoller L, Petersen HH, Andreasen PA.
    Biochem J; 1998 Jan 01; 329 ( Pt 1)(Pt 1):55-63. PubMed ID: 9405275
    [Abstract] [Full Text] [Related]

  • 14. Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system.
    Heiss MM, Babic R, Allgayer H, Gruetzner KU, Jauch KW, Loehrs U, Schildberg FW.
    J Clin Oncol; 1995 Aug 01; 13(8):2084-93. PubMed ID: 7636552
    [Abstract] [Full Text] [Related]

  • 15. Kinetic analysis of plasminogen activator inhibitor type-2: urokinase complex formation and subsequent internalisation by carcinoma cell lines.
    Al-Ejeh F, Croucher D, Ranson M.
    Exp Cell Res; 2004 Jul 01; 297(1):259-71. PubMed ID: 15194441
    [Abstract] [Full Text] [Related]

  • 16. Urokinase/urokinase receptor system: internalization/degradation of urokinase-serpin complexes: mechanism and regulation.
    Conese M, Blasi F.
    Biol Chem Hoppe Seyler; 1995 Mar 01; 376(3):143-55. PubMed ID: 7612191
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size.
    Abe J, Urano T, Konno H, Erhan Y, Tanaka T, Nishino N, Takada A, Nakamura S.
    Cancer; 1999 Dec 15; 86(12):2602-11. PubMed ID: 10594855
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.